openPR Logo
Press release

ExiScale Surpasses $500 million in Ad Spend, Bringing Massive Growth for Meta Advertisers

08-01-2025 06:30 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

ExiScale Surpasses $500 million in Ad Spend, Bringing Massive

ExiScale has officially crossed the $500 million mark in client ad spend, a significant milestone that highlights its growing reputation as the trusted infrastructure behind many of today's top-performing Meta advertisers. This achievement reflects the confidence that eCommerce brands, agencies, and performance marketers have placed in ExiScale to keep their advertising operations running seamlessly despite Meta's increasingly restrictive environment.

Designed specifically for media buyers who can't afford downtime, ExiScale [https://exiscale.com/] provides aged Facebook profiles, premium Business Managers, and reliable high-trust ad accounts. Each account is supported by 24/7 live assistance and comes with a lifetime replacement guarantee, ensuring advertisers can scale without disruption or fear of bans.

"Crossing half a billion in ad spend validates what we've known all along: advertisers don't just need access to ad accounts; they need a dependable infrastructure they can trust," said Kyron Hellmrich, CEO of ExiScale. "This isn't about luck. It's about consistent performance, accountability, and the ability to deliver results at scale."

Here's why thousands of media buyers trust ExiScale:

*
Instant-ready, aged Facebook profiles with established trust

*
Robust Business Managers and vetted Meta ad accounts

*
Clean, reliable U.S.-based IPs. No more of those flagged or proxy data centers

*
Transparent onboarding and setup process with no hidden pitfalls

*
Lifetime replacement guarantee for peace of mind

*
Round-the-clock expert support for uninterrupted operations

In the words of the company's representative, "Whether you're running affiliate offers, managing agency accounts, or scaling your own eCommerce brand, ExiScale has emerged as the go-to solution for advertisers looking to run Facebook ads without hassle."

As the company pushes beyond the $500 million milestone, it continues to prove that reliable advertising infrastructure is the key to long-term growth.

Learn more or get started today at https://exiscale.com [https://exiscale.com/].

For any inquiry, email Kyron Hellmrich at support@exiscale.com

Media Contact
Company Name: ExiScale
Contact Person: Kyron Hellmrich
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exiscale-surpasses-500-million-in-ad-spend-bringing-massive-growth-for-meta-advertisers]
City: Sheridan
State: Wyoming
Country: United States
Website: http://exiscale.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release ExiScale Surpasses $500 million in Ad Spend, Bringing Massive Growth for Meta Advertisers here

News-ID: 4130210 • Views:

More Releases from ABNewswire

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our
Retinal Vein Occlusion Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Retinal Vein Occlusion Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Retinal Vein Occlusion Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore

All 5 Releases